1. Pharmacokinetics and metabolism features
Absorption of the drug from the gastrointestinal tract occurs quite well and completely. However, in clinical pharmacology, it is important not to confuse good absorption with high final bioavailability. In the case of diltiazem (Diltiazemum), bioavailability remains at an extremely low level, varying within 20–35%.
The main reason for such massive losses of the active substance is pronounced presystemic metabolism (first-pass effect through the liver). In this regard, the drug demonstrates complete similarity to verapamil (Verapamilum). Test questions often try to confuse students by offering renal clearance, enterohepatic circulation, or high plasma protein binding as reasons for low drug concentrations in the blood. Do not fall for these tricks: the correct answer lies exclusively in presystemic metabolism.
Regarding temporal parameters, the drug has its own specific features:
- Onset of action: the clinical effect develops within 30 minutes after administration, which advantageously distinguishes it from verapamil (diltiazem acts faster).
- Half-life ($t_{1/2}$): remains relatively short, ranging from 3 to 4 hours, which requires a specific dosing regimen.
- Elimination: the excretion of metabolites from the body is carried out predominantly through the intestines.
2. Pharmacodynamics and indications
To easily grasp the mechanism of action of diltiazem, it is enough to recall the pharmacodynamics of verapamil. The working principle of these two drugs is completely analogous. Diltiazem is not limited to an isolated effect solely on the myocardium or solely on peripheral vessels; it demonstrates a powerful combination of cardiac and vascular effects.
When asked on an exam to compare the mechanism of action of various calcium channel blockers, remember that diltiazem is a functional analogue of verapamil. In its profile, it is completely unlike dihydropyridine derivatives, such as amlodipine (Amlodipinum) or nifedipine (Nifedipinum), which have predominantly vascular effects and minimal impact on the heart's conduction system.
Based on the dual mechanism of action, indications for use logically follow. They completely duplicate the indications for verapamil:
- Relief and prevention of angina attacks (coronary artery disease).
- Treatment and rate control in various arrhythmias.
3. Side effect profile: differences from analogues
The most important part of the topic for a practicing physician is adverse reactions. This is precisely where the main clinical difference between diltiazem and verapamil lies. Despite sharing indications and a mechanism of action, their safety profiles have distinct individual features that often form the basis of clinical cases.
While verapamil is traditionally associated with bradycardia, atrioventricular (AV) block, and pronounced constipation, diltiazem presents a different pattern of complications. Patients receiving diltiazem may experience the following side effects:
- Hypotension — excessive drop in blood pressure due to vasodilation.
- Tachycardia — increased heart rate (often reflex in response to a drop in blood pressure).
- Headache — a classic consequence of cerebral vasodilation.
- Edema — peripheral edema, typical of many drugs with a vascular component of action.
- Muscle cramps — a very specific symptom that often acts as a marker for this particular drug in tests.
Briefly: answers to topical questions
What is the exact cellular mechanism of action of diltiazem?
The exact cellular mechanism of action of diltiazem consists in the selective blockade of L-type voltage-gated calcium channels. The drug's target is the $\alpha_1$-subunit of the channel, which acts as a voltage-sensitive sensor. Normally, upon cell membrane depolarization, these channels open, allowing calcium ions to enter the cell and increasing their concentration in the cytoplasm, which triggers muscle contraction. By blocking this process, diltiazem exerts combined cardiac and vascular effects, since L-type channels are localized in cardiac myocytes and smooth muscle cells of resistance vessels.
What are the absolute contraindications to prescribing diltiazem?
There is no direct list of absolute contraindications for prescribing diltiazem in the sources. The mandatory conditions for use include the absence of symptoms of heart failure, significant left ventricular systolic dysfunction, sinoatrial and AV conduction disorders, and bradyarrhythmias. In chronic heart failure, diltiazem administration must be stopped due to the high risk of bradycardia and depression of contractility.
Which drug groups are dangerous to combine with diltiazem?
Diltiazem should be combined with caution or avoided with:
- Beta-blockers — co-administration is highly undesirable.
- Antineoplastic drugs sensitive to CYP3A4 and/or P-glycoprotein interactions — diltiazem can alter their pharmacokinetics and exacerbate heart failure caused by cardiotoxic medications.
- Immunosuppressants — diltiazem inhibits CYP3A4 and P-glycoprotein, which can increase blood concentrations of immunosuppressants; monitoring and dosage adjustment of immunosuppressive therapy are required.
To avoid confusing side effects in tests, remember the contrast: Verapamil "slows down" (bradycardia, AV block, constipation), while Diltiazem "speeds up and causes spasms" (tachycardia, muscle cramps, headache).
Class and exam questions
Why does diltiazem have low bioavailability despite good gastrointestinal absorption?
This is a classic example of the effect of presystemic metabolism. The drug is well absorbed in the intestine, but during the first pass through the liver, most of it is destroyed by enzymes before reaching the systemic circulation. This distinguishes it from drugs whose concentration drops due to renal clearance or protein binding.
What is the main pharmacokinetic difference between diltiazem and verapamil?
The key difference lies in the onset of the effect. Diltiazem starts working much faster — within 30 minutes of administration. At the same time, its half-life is 3–4 hours, and it is excreted predominantly through the intestines.
How do the side effects of diltiazem and verapamil differ?
Despite a similar mechanism of action (cardiac and vascular effects) and general indications (angina, arrhythmias), their adverse reactions differ. Diltiazem is characterized by tachycardia, hypotension, edema, headache, and muscle cramps. Verapamil, on the other hand, more often causes bradycardia, AV block, and constipation.
What else to study on this topic
- Presystemic metabolism of drugs (first-pass effect through the liver).
- Comparative pharmacodynamics of verapamil, amlodipine, and nifedipine.
- Mechanisms of peripheral edema development when taking drugs with a vascular action.
- Pharmacological correction of arrhythmias and angina: drug selection.
- Elimination pathways of drugs: intestinal elimination vs. renal clearance.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Diltiazem" and 5,304 more subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Cardiovascular Drugs"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.